Baricitinib with HIV treatment to lower hidden virus
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests if adding the drug baricitinib to your regular HIV treatment can reduce the amount of virus hiding in your body, which might help control HIV better or even lead to a cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HIV and have been taking HIV medications without stopping for at least 96 weeks.
- Your viral load (amount of virus in your blood) must be below 50 copies/mL for at least 96 weeks and at your most recent test before joining.
- Your CD4 count (a sign of your immune system health) must be 500 or higher at your most recent check.
- You must not have had a CD4 count below 200 in the past.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study.
- You must not have had certain infections, heart problems, blood clots, or cancers that the study excludes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
This trial tests if two drugs, baricitinib and sirolimus, can help control HIV after stopping standard antiretroviral therapy (ART). It aims to see if these immune treatments allow patients to maintain viral suppression without daily pills.
This early-stage trial tests whether two drugs work together to reduce hidden HIV in your body while you're on stable HIV treatment. The goal is to understand how safe the combination is and whether it helps clear dormant HIV cells.
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.